Clinical Trial Search

Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 87.8; 88.2; 6.3; 5.9…

Primary: Number of Cigarettes Smoked Per Day — 15.4; 14.9 number of cigarettes — p=0.489

Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 78.4; 77.5; 16.6; 18.4…

Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 75; 80; 20.3; 14.9 Percentage…

Primary: Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26 — 32.9; 84.9 Percentage of Participants

Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33

Primary: Baseline Mean Pain Score — 6.65; 6.67 units on a scale

Primary: Percentage of American College of Rheumatology [ACR] 20 Criteria Responders — 69.5; 30.7; NA; 71.3 Percentage of Participants

Primary: Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D) — -8.19; -7.83; -13.6 units on a scale

Primary: Adverse Event — 37 Subjects

Primary: Hematocrit (Hct) — 29.2; 28.3 percentage of red blood cells in blood

Primary: Tinnitus Handicap Questionnaire (THQ) — 3.75; 4.02 units on a scale

Primary: Time to Relapse During the Double-Blind Phase — 395.0; NA Days

Primary: Occurence of Factor IX (FIX) Inhibitor Development — 0; 0; 0; 0 percentage of participants

Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC) — 2.5; 26.9…